Advaxis, Inc. (NASDAQ:ADXS) was founded in 2002 and is headquartered in Princeton, New Jersey, USA, with 58 full-time employees. It is a clinical stage biotechnology company focusing on the research and development of LM-LLO cancer immunotherapy in the United States And commercial applications.
Advaxis, Inc. is a late-stage biotechnology company focusing on the discovery, development and commercialization of antigen delivery products based on Listeria monocytogenes (Lm) technology in the United States.
Advaxis is developing a treatment method for HPV-related cancers using axalimogene filolisbac (AXAL) to treat head and neck cancer.
Advaxis is also developing ADXS-PSA for the treatment of prostate cancer; and ADXS-NEO, an individualized Lm technology antigen delivery product candidate designed to activate the patient’s immune system to respond to multiple mutations or new antigens Create personalized therapy.
In addition, Advaxis is developing ADXS-HOT to generate effective anti-cancer immunity; and ADXS-HER2, a candidate for Lm technology antigen delivery product, designed to target HER2 expressing solid tumors, including human and canine osteosarcoma.
Advaxis (ADXS) investment:
The research directions, platforms and products of ADXS are highly consistent with ADRO. Therefore, the investment of ADXS can refer to the introduction of ADRO . Other similar clinical stage anticancer drug companies can also pay attention to: BLUE , KITE , JUNO , BLCM, etc.